secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027168
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M
--------------------------------------------------------------------------------

- Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.
- Operating income fell to $30K from $585K in the year-ago quarter.
- Net loss of $35K ($0.00 EPS) vs net income of $516K ($0.02) in Q1 FY2022.
- Two largest Contract Manufacturing customers were 85% of revenue (down from 91%).
- Co-CEOs cite pandemic overstocking by customers as key headwind.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/0001437749-22-027168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/inbp20221110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer